Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Cerus Corp director Eric Bjerkholt sold shares in an open-market transaction. On this trade, he sold 20,454 shares of Cerus common stock at a price of $2.60 per share. After the sale, he directly owned 261,679 shares of the company’s common stock.
Cerus Corporation entered into new secured credit agreements that refinance and expand its debt facilities. The term loan agreement provides up to $65.0 million, of which $35.0 million was drawn on closing to refinance existing term loans, after having repaid $30.0 million under the prior term facility. An additional $30.0 million term tranche may be requested in minimum $5.0 million increments for working capital and general corporate purposes.
The revolving credit agreement provides an initial $30.0 million borrowing base-driven revolver, with potential to increase commitments by $15.0 million. As of the closing date, $29.9 million was outstanding. Term loans bear interest at Term SOFR plus 5.50%, and revolver borrowings at Term SOFR plus 3.70%, each with a 1.00% SOFR floor. Cerus’s obligations are secured by substantially all assets and are subject to revenue-based financial covenants and customary negative covenants and events of default.
Cerus Corporation reported results from its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2024 Equity Incentive Plan, increasing the common stock available for issuance under the plan by 10,000,000 shares.
Stockholders also elected William M. Greenman and Ann Lucena to the board to serve until the 2029 Annual Meeting. In additional votes, shareholders approved on an advisory basis the compensation of named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Lucena Ann reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Ann Lucena received a grant of 60,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one share. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to her continuous service. Following this award, she holds 232,284 shares directly.
Cerus Corp director Eric Bjerkholt received an equity grant rather than buying shares on the market. He was awarded 60,000 shares of common stock in the form of restricted stock units (RSUs) under Cerus’ 2024 Equity Incentive Plan at no cash cost.
Each RSU converts into one share of common stock if it vests. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as he continues to serve the company. After this grant, he directly holds 282,133 shares.
NACHTSHEIM JAMI K reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Jami K. Nachtsheim received an equity grant of 60,000 restricted stock units (RSUs). These RSUs were awarded at no cash cost per unit and increase her direct holdings to 268,362 shares of common stock.
Each RSU represents a contingent right to receive one share of Cerus common stock. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as she continues serving the company through that vesting date.
CERUS CORP Chief Operating Officer Vivek K. Jayaraman sold shares in an open-market transaction. On May 29, 2026, he sold 16,667 shares of Cerus common stock at $3.00 per share in a sale reported as an open-market transaction.
The filing states that this transaction was executed pursuant to a Rule 10b5-1 trading plan, meaning it was pre-arranged rather than timed discretionarily. Following the sale, Jayaraman directly owned 1,656,707 shares of Cerus common stock.
Witney Frank reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Frank Witney reported an equity grant of 60,000 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs were granted under Cerus’s 2024 Equity Incentive Plan, with each RSU representing a contingent right to receive one share of common stock.
The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of stockholders, as long as Witney remains in continuous service with Cerus through that vesting date. Following this grant, he directly holds 340,059 shares of common stock.
Cerus Corp director Gregory Dean A. reported receiving 60,000 shares of common stock in the form of restricted stock units (RSUs) granted under the company’s 2024 Equity Incentive Plan. Each RSU converts into one share and vests on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as he continues serving the company. After this award, he directly holds 146,725 shares of Cerus common stock.